Option chain shows key data for Unicycive Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Unicycive Therapeutics.

Unicycive Therapeutics (NASDAQ:UNCY) Stock, Option Chain

UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

The Greenbrier Company

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

FBIO

NWGL

UNCY

Greenbrier, Fortress Biotech And 3 Stocks To Watch Heading Into Monday

Penny Stocks

Small Cap

Intraday Update

Movers

AFRM

AUUD

BTTX

CCTG

FUTU

FWBI

GIII

HEAR

HGAS

HOOD

IMRX

KPLT

MDGL

MOMO

NOVA

PANL

PATH

PERF

PIXY

PRST

PUYI

RAYA

RCMT

RGLS

RMBL

SPRB

SPRO

TCON

WIMI

WOOF

Shares of  Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

AGFY

ARAV

BABA

BETS

BILI

BREA

CLEU

CSIQ

DADA

ENSC

ESGL

ETAO

EVAX

FAZE

GPAK

GYRE

IBRX

LIFW

LOGI

MARK

MESO

NUTX

NVVE

PLUG

REVB

RVSN

SAVE

SGMT

SLDP

SRTS

VTAK

Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates.

Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics Inc

Press Releases

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

Health Care

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

General

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics

Analyst Ratings

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360

Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Aligos Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

BeyondSpring

Cibus

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

CervoMed

Cue Biopharma

IGM Biosciences

I-MAB

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Inozyme Pharma

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Metagenomi

MediciNova

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OSR Holdings

PMV Pharma

Pyxis Oncology

Quince Therapeutics

Skye Bioscience

Sutro Biopharma

HC Wainwright & Co.

Benchmark

Piper Sandler

Noble Capital Markets

EF Hutton

Comments

Unicycive Therapeutics

Unicycive Therapeutics (UNCY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga